Testing an antiviral’s effects in early COVID-19
Treatments studied
Part of Infections, Lungs & breathing clinical trials.
This trial looks at how well an antiviral works in the body when started early in people with COVID-19 symptoms. You may be able to join if you’re an otherwise healthy adult with confirmed infection and symptoms for less than 4 days.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must understand the study and sign informed consent
- You’re 18 to 60 years old and otherwise healthy
- You have early COVID-19 symptoms for less than 4 days
- Your COVID test is positive very recently (within 24 hours for PCR) or a positive rapid test
- Your oxygen level is at least 96% at screening and you can walk normally
- You can follow study visits and contact instructions for follow-up
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial studies whether PF-07321332 (with ritonavir) helps children under 18 who have COVID-19 at home but are at high risk of severe illness. It looks at whether starting treatment early can reduce progression to worse disease.
This trial tests a new drug, ratutrelvir, for people with mild to moderate COVID-19. It aims to find a safe and effective dose to help you feel better faster.
This trial studies a longer course of remdesivir combined with nirmatrelvir/ritonavir (Paxlovid) for immunocompromised patients who have persistent COVID-19. The goal is to see if this combination helps clear the virus better.
This trial tests whether Codivir can help people hospitalized with moderate COVID-19 recover better than a placebo (inactive pill). It will compare outcomes while participants receive standard hospital care.
This trial tests whether an optimized antiviral treatment can help people with weakened immune systems who have COVID-19. It aims to find the best way to treat them to prevent severe illness.
This study tests the best combination and timing of antiviral medicines for people with COVID-19 who have weakened immune systems. It aims to improve outcomes in people with mild to moderate illness.
Hear when a new COVID-19 trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.